Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage oncology company focused on antibody drug conjugates, and its news flow centers on clinical progress, regulatory developments, and corporate updates. The company’s primary product, ZYNLONTA (loncastuximab tesirine-lpyl), is a CD19-directed ADC approved under accelerated and conditional pathways for certain adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapies.
News about ADCT commonly includes updates from its LOTIS clinical program, such as the Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab in second-line or later DLBCL and the Phase 1b LOTIS-7 trial evaluating ZYNLONTA in combination with bispecific antibodies and other agents in B-cell non-Hodgkin lymphoma. Company releases have highlighted response rates, safety findings, and enrollment milestones from LOTIS-7, as well as anticipated timelines for sharing full data and pursuing regulatory and compendia strategies.
Investors and followers of ADCT news will also find announcements on preliminary revenue and cash estimates, participation in healthcare conferences, and equity-related actions such as employee inducement grants and private placements. These items appear in both press releases and related Form 8-K filings, giving context on the company’s commercial performance and financing plans alongside its clinical pipeline.
This news page aggregates such disclosures so readers can track ADCT’s key events, from clinical trial readouts and investigator-initiated study updates in indolent lymphomas to progress on its early-stage PSMA-targeting ADC. For those monitoring ADCT stock, revisiting this page provides a consolidated view of the company’s evolving clinical, regulatory, and corporate narrative.
ADC Therapeutics (NYSE: ADCT) announced a series of strategic transactions, including a new $175 million senior secured term loan with Owl Rock and Oaktree Capital Management. The company settled $115 million of convertible notes with Deerfield Management, in which Deerfield took equity as part of the settlement. An additional investment of $6.25 million for common shares was made by Owl Rock. The new debt facility, maturing in 2029, helps maintain liquidity into early 2025, supporting the advancement of ADC Therapeutics' cancer treatments.
ADC Therapeutics reported financial results for the second quarter of 2022, highlighting net sales for ZYNLONTA® at $17.3 million, up from $3.8 million year-over-year. The company established a license agreement with Sobi® to enhance global access to ZYNLONTA, extending its cash runway to early 2025. Notable advancements include the initiation of multiple clinical trials, including LOTIS-9 and LOTIS-7. Net loss for the quarter was $64.4 million, showing an improvement compared to the previous year. ADC's focus on increasing product awareness is expected to support ongoing growth.
ADC Therapeutics (NYSE: ADCT) announced a conference call and webcast scheduled for August 9, 2022, at 8:30 a.m. ET to disclose its Q2 2022 financial results and share business updates. The call will provide investors with insights into the company’s performance and operations. ADC Therapeutics specializes in targeted antibody drug conjugates for cancer treatment, including the FDA-approved ZYNLONTA for diffuse large B-cell lymphoma, and ongoing developments in its ADC pipeline.
ADC Therapeutics announced the initiation of a Phase 1b clinical trial for ADCT-601 (mipasetamab uzoptirine), targeting AXL in patients with advanced solid tumors. The trial aims to assess ADCT-601's safety as a standalone and in combination with gemcitabine, particularly in sarcoma, a tumor resistant to current treatments. ADCT-601 has shown a manageable tolerability profile and promising preclinical synergy with gemcitabine. This advancement continues ADC Therapeutics' focus on improving cancer treatment through targeted antibody-drug conjugates.
ADC Therapeutics has initiated the LOTIS-9 Phase 2 clinical trial, targeting unfit and frail patients with previously untreated DLBCL. This trial aims to evaluate the efficacy and tolerability of ZYNLONTA (loncastuximab tesirine-lpyl) combined with rituximab in approximately 80 patients aged 80 and older. The trial follows promising results from the LOTIS-5 Phase 3 trial, addressing a significant medical need in a typically underserved population. The study may pave the way for new treatment options for these patients.
Overland ADCT BioPharma has initiated its Phase 3 LOTIS-5 trial in China, dosing the first patient with ZYNLONTA® combined with rituximab for DLBCL. This follows ZYNLONTA's accelerated FDA approval as a single-agent therapy for relapsed DLBCL. The trial aims to support a supplemental BLA in the U.S. and China for transplant-ineligible patients. This significant milestone reflects the commitment to advancing treatment options for patients with difficult-to-treat DLBCL in China.
Summary not available.
ADC Therapeutics announced the appointment of Jean-Pierre Bizzari, MD, to its Board of Directors, enhancing its oncology expertise. Ameet Mallik, CEO since May 2022, also joins the Board. Dr. Bizzari brings over 35 years of experience, having previously overseen critical oncology product developments at Celgene and Sanofi-Aventis. His extensive background is expected to bolster ADC Therapeutics' pipeline of antibody drug conjugates for treating hematological cancers and solid tumors, especially after the FDA approval of ZYNLONTA®.
ADC Therapeutics has announced the dosing of the first patient in the LOTIS-7 Phase 1b clinical trial, examining the efficacy of ZYNLONTA in combination with polatuzumab vedotin for treating relapsed or refractory B-cell non-Hodgkin lymphoma.
The trial aims to evaluate ZYNLONTA's safety and activity against various types of B-cell lymphomas, with a focus on achieving better responses in patients. This trial follows promising preclinical studies that indicated potential synergies with other therapies.
ADC Therapeutics has appointed David Gilman as the new Chief Business & Strategy Officer, effective July 1st. With over 25 years of experience in the life sciences sector, Gilman will be responsible for global business development and portfolio strategy, reporting directly to CEO Ameet Mallik. His previous roles include Global Head of Portfolio Strategy at Novartis and significant contributions at ClearView Healthcare Partners.
This strategic appointment aims to strengthen ADC Therapeutics' leadership at a critical time for the company.